search
Back to results

The Effect of Local Anaesthetic Volume on Nerve Block Duration and Nerve Block Duration Variability

Primary Purpose

Postoperative Pain

Status
Completed
Phase
Phase 4
Locations
Denmark
Study Type
Interventional
Intervention
Ropivacaine
Sponsored by
Nordsjaellands Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Postoperative Pain focused on measuring Regional anaesthesia

Eligibility Criteria

18 Years - 64 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion criteria

  1. Male or female 18-64 years
  2. American Society of Anesthesiologists Classification ≤ II

Exclusion criteria

  1. Body Mass Index ≤ 18 or ≥ 30
  2. Former surgery to the lower extremities
  3. Peripheral nerve disease
  4. Allergy to ropivacaine
  5. Pregnancy or breastfeeding
  6. Enrolment in other investigational drug studies or recent clinical trials that may interfere with this study
  7. Habitual use of any kind of analgesic treatment
  8. Anatomic abnormalities preventing successful US-guided peripheral nerve catheter insertion

Sites / Locations

  • Claus Behrend Christiansen

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm 9

Arm 10

Arm Type

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Arm Label

Peroneal nerve: Ropivacaine 0.2%, 2.5 mL

Peroneal nerve: Ropivacaine 0.2%, 5 mL

Peroneal nerve: Ropivacaine 0.2%, 10 mL

Peroneal nerve: Ropivacaine 0.2%, 15 mL

Peroneal nerve: Ropivacaine 0.2%, 20 mL

Sciatic nerve: Ropivacaine 0.2%, 5 mL

Sciatic nerve: Ropivacaine 0.2%, 10 mL

Sciatic nerve: Ropivacaine 0.2%, 15 mL

Sciatic nerve: Ropivacaine 0.2%, 20 mL

Sciatic nerve: Ropivacaine 0.2%, 30 mL

Arm Description

Perineural injection of ropivacaine 0.2 %, 2,5 mL

Perineural injection of ropivacaine 0.2 %, 5 mL

Perineural injection of ropivacaine 0.2 %, 10 mL

Perineural injection of ropivacaine 0.2 %, 15 mL

Perineural injection of ropivacaine 0.2 %, 20 mL

Perineural injection of ropivacaine 0.2 %, 5 mL

Perineural injection of ropivacaine 0.2 %, 10 mL

Perineural injection of ropivacaine 0.2 %, 15 mL

Perineural injection of ropivacaine 0.2 %, 20 mL

Perineural injection of ropivacaine 0.2 %, 30 mL

Outcomes

Primary Outcome Measures

Duration of sensory nerve block
Application of a round, cooled glass container in the sensory distribution area of the tested nerve: The lateral part of the lower leg for the common peroneal nerve and beneath the foot for the tibial nerve. Testing will start after onset of sensory nerve block and continue until normal sensation has returned. When testing the sciatic nerve, we will continue testing until normal sensation has returned in both components of the nerve, i.e. the tibial and common peroneal nerve.

Secondary Outcome Measures

Length of nerve exposed to local anaesthesia
We will measure local anaesthetic spread in a proximal-to-distal manner parallel to the nerve trajectory. Total length of the neural spread will be reported in millimetres from the most proximal point to the most distal point in which fluid, i.e. ropivacaine, is seen on ultrasound in proximity to the nerve. Testing will be done immediately after end of ropivacaine infusion.
Onset of sensory nerve block
Application of a round, cooled glass container in the sensory distribution area of the tested nerve: The lateral part of the lower leg for the common peroneal nerve and beneath the foot for the tibial nerve. Testing will start ten minutes after end of infusion and continue for every fifth minute until onset. We will test for a maximum of 180 minutes.
Onset of motor nerve block
Testing will start ten minutes after end of infusion and continue for every fifth minute until onset. When onset of sensory nerve block is confirmed, testing of motor nerve block onset will end as well, if not already found. Motor nerve block of the tibial nerve will be evaluated by plantarflexion of the ankle. Motor nerve block of the common peroneal nerve will be tested by dorsiflexion of the ankle.
Degree of sensory nerve block
We will test sensory nerve block using a subjective rating scale. We will grade from one to four: 1) "not different from ipsilateral antebrachium"; 2) "different from ipsilateral antebrachium"; 3) "warm sensation"; 4) "no sensation". Grades 2-4 will be considered as successful sensory nerve blocks. It will be noted if the volunteer is in doubt. Nevertheless, this will be considered as a successful sensory nerve block and graded as 2) in the post hoc statistical analyses.
Degree of motor nerve block
This will be tested with the volunteer in the upright position using a sturdy counter for balance if necessary. Motor strength will be evaluated using a normal everyday activation of the lower leg: A toe and a heel raise, testing the common peroneal nerve via activation of the anterior tibial muscle and the tibial nerve via activation of the gastrocnemius muscle, respectively. Motor nerve block intensity will be evaluated on a scale from one to three: 1) normal strength, 2) paresis or 3) paralysis. Volunteers will be asked to perform a maximum contraction building up muscle force over three seconds. It will be noted if the volunteer is in doubt, which will be considered as 2) paresis in the post hoc statistical analyses.

Full Information

First Posted
July 8, 2016
Last Updated
March 20, 2017
Sponsor
Nordsjaellands Hospital
Collaborators
Innovation Fund Denmark
search

1. Study Identification

Unique Protocol Identification Number
NCT02829697
Brief Title
The Effect of Local Anaesthetic Volume on Nerve Block Duration and Nerve Block Duration Variability
Official Title
The Effect of Local Anaesthetic Volume on Nerve Block Duration and Nerve Block Duration Variability. A Randomised, Blinded, Healthy Volunteer Study
Study Type
Interventional

2. Study Status

Record Verification Date
March 2017
Overall Recruitment Status
Completed
Study Start Date
July 2016 (undefined)
Primary Completion Date
March 20, 2017 (Actual)
Study Completion Date
March 20, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Nordsjaellands Hospital
Collaborators
Innovation Fund Denmark

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The aim is to investigate the effect of perineural administration of a series of different volumes of local anaesthesia (ropivacaine 0.2%) on nerve block duration and the variability of the duration in the common peroneal nerve and the sciatic nerve in healthy volunteers. The hypothesis is that nerve block duration is correlated to local anaesthetic volume, but only to a certain degree. After a sufficient volume a 'saturation level' will be reached, and nerve block duration will not increase further.
Detailed Description
The trial is divided into two similar phases. Each phase will focus on a specific nerve. Phase 1 will focus on the common peroneal nerve and Phase 2 will focus on the sciatic nerve. After baseline measurements, the investigators will insert a peripheral intravenous catheter. Then, the investigators will insert a suture-method peripheral nerve catheter (Certa CatheterTM). Procedures will be done in a sterile manner as a standard of practice. The investigators will use an ultrasound (US)-guided short-axis, needle in-plane technique. For the US-scan, the investigators will use a linear or a curvilinear transducer. During interventions, volunteers will be monitored with continuous pulse oximetry. Placement of the peripheral nerve catheter will be facilitated by US using small injections of mepivacaine (carbocaine 2 %) in the skin and surrounding tissues and only isotonic saline (5 mL) in the perineural space to prevent blocking of the nerve before ropivacaine injection. The catheter orifice will be placed by pulling either end of the catheter and guided by the built-in echogenic markings seen on US. Before injection of ropivacaine, the investigators will do careful aspirations through the catheter in order to prevent intravasal injection. Each ropivacaine injection will be administered via an infusion pump. This will ensure a constant infusion rate set to 10 mL per minute. During infusion, the volunteers will be monitored with continuous pulse oximetry. Before instigation of the ropivacaine infusion, the investigators will use US to verify full absorption of the isotonic saline in the perineural space. For each nerve, the subject will be randomly allocated to and receive one of five possible ropivacaine volumes. All volunteers and outcome assessors will be blinded to the ropivacaine administrations and infusion procedures. Outcome assessors will not be in the room, when the medication is prepared nor given. Preparation will take place behind a curtain and therefore also blinded to the volunteers.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postoperative Pain
Keywords
Regional anaesthesia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
120 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Peroneal nerve: Ropivacaine 0.2%, 2.5 mL
Arm Type
Active Comparator
Arm Description
Perineural injection of ropivacaine 0.2 %, 2,5 mL
Arm Title
Peroneal nerve: Ropivacaine 0.2%, 5 mL
Arm Type
Active Comparator
Arm Description
Perineural injection of ropivacaine 0.2 %, 5 mL
Arm Title
Peroneal nerve: Ropivacaine 0.2%, 10 mL
Arm Type
Active Comparator
Arm Description
Perineural injection of ropivacaine 0.2 %, 10 mL
Arm Title
Peroneal nerve: Ropivacaine 0.2%, 15 mL
Arm Type
Active Comparator
Arm Description
Perineural injection of ropivacaine 0.2 %, 15 mL
Arm Title
Peroneal nerve: Ropivacaine 0.2%, 20 mL
Arm Type
Active Comparator
Arm Description
Perineural injection of ropivacaine 0.2 %, 20 mL
Arm Title
Sciatic nerve: Ropivacaine 0.2%, 5 mL
Arm Type
Active Comparator
Arm Description
Perineural injection of ropivacaine 0.2 %, 5 mL
Arm Title
Sciatic nerve: Ropivacaine 0.2%, 10 mL
Arm Type
Active Comparator
Arm Description
Perineural injection of ropivacaine 0.2 %, 10 mL
Arm Title
Sciatic nerve: Ropivacaine 0.2%, 15 mL
Arm Type
Active Comparator
Arm Description
Perineural injection of ropivacaine 0.2 %, 15 mL
Arm Title
Sciatic nerve: Ropivacaine 0.2%, 20 mL
Arm Type
Active Comparator
Arm Description
Perineural injection of ropivacaine 0.2 %, 20 mL
Arm Title
Sciatic nerve: Ropivacaine 0.2%, 30 mL
Arm Type
Active Comparator
Arm Description
Perineural injection of ropivacaine 0.2 %, 30 mL
Intervention Type
Drug
Intervention Name(s)
Ropivacaine
Intervention Description
Perineural injection.
Primary Outcome Measure Information:
Title
Duration of sensory nerve block
Description
Application of a round, cooled glass container in the sensory distribution area of the tested nerve: The lateral part of the lower leg for the common peroneal nerve and beneath the foot for the tibial nerve. Testing will start after onset of sensory nerve block and continue until normal sensation has returned. When testing the sciatic nerve, we will continue testing until normal sensation has returned in both components of the nerve, i.e. the tibial and common peroneal nerve.
Time Frame
1-24 hours
Secondary Outcome Measure Information:
Title
Length of nerve exposed to local anaesthesia
Description
We will measure local anaesthetic spread in a proximal-to-distal manner parallel to the nerve trajectory. Total length of the neural spread will be reported in millimetres from the most proximal point to the most distal point in which fluid, i.e. ropivacaine, is seen on ultrasound in proximity to the nerve. Testing will be done immediately after end of ropivacaine infusion.
Time Frame
10 minutes
Title
Onset of sensory nerve block
Description
Application of a round, cooled glass container in the sensory distribution area of the tested nerve: The lateral part of the lower leg for the common peroneal nerve and beneath the foot for the tibial nerve. Testing will start ten minutes after end of infusion and continue for every fifth minute until onset. We will test for a maximum of 180 minutes.
Time Frame
10-180 minutes
Title
Onset of motor nerve block
Description
Testing will start ten minutes after end of infusion and continue for every fifth minute until onset. When onset of sensory nerve block is confirmed, testing of motor nerve block onset will end as well, if not already found. Motor nerve block of the tibial nerve will be evaluated by plantarflexion of the ankle. Motor nerve block of the common peroneal nerve will be tested by dorsiflexion of the ankle.
Time Frame
10-180 minutes
Title
Degree of sensory nerve block
Description
We will test sensory nerve block using a subjective rating scale. We will grade from one to four: 1) "not different from ipsilateral antebrachium"; 2) "different from ipsilateral antebrachium"; 3) "warm sensation"; 4) "no sensation". Grades 2-4 will be considered as successful sensory nerve blocks. It will be noted if the volunteer is in doubt. Nevertheless, this will be considered as a successful sensory nerve block and graded as 2) in the post hoc statistical analyses.
Time Frame
1-24 hours
Title
Degree of motor nerve block
Description
This will be tested with the volunteer in the upright position using a sturdy counter for balance if necessary. Motor strength will be evaluated using a normal everyday activation of the lower leg: A toe and a heel raise, testing the common peroneal nerve via activation of the anterior tibial muscle and the tibial nerve via activation of the gastrocnemius muscle, respectively. Motor nerve block intensity will be evaluated on a scale from one to three: 1) normal strength, 2) paresis or 3) paralysis. Volunteers will be asked to perform a maximum contraction building up muscle force over three seconds. It will be noted if the volunteer is in doubt, which will be considered as 2) paresis in the post hoc statistical analyses.
Time Frame
1-24 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
64 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion criteria Male or female 18-64 years American Society of Anesthesiologists Classification ≤ II Exclusion criteria Body Mass Index ≤ 18 or ≥ 30 Former surgery to the lower extremities Peripheral nerve disease Allergy to ropivacaine Pregnancy or breastfeeding Enrolment in other investigational drug studies or recent clinical trials that may interfere with this study Habitual use of any kind of analgesic treatment Anatomic abnormalities preventing successful US-guided peripheral nerve catheter insertion
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kai Henrik Wiborg Lange, MD DMSC
Organizational Affiliation
Nordsjællands Hospital Hillerød
Official's Role
Study Director
Facility Information:
Facility Name
Claus Behrend Christiansen
City
Hillerød
ZIP/Postal Code
DK-3400
Country
Denmark

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
We will attach relevant data sheets to all our scientific submissions.

Learn more about this trial

The Effect of Local Anaesthetic Volume on Nerve Block Duration and Nerve Block Duration Variability

We'll reach out to this number within 24 hrs